1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Atrial Septal Defect Global Clinical Trials Review, H2, 2016

Atrial Septal Defect Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Atrial Septal Defect Global Clinical Trials Review, H2, 2016" provides an overview of Atrial Septal Defect clinical trials scenario. This report provides top line data relating to the clinical trials on Atrial Septal Defect. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Atrial Septal Defect Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2


Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Clinical Trials by G7 Countries: Proportion of Atrial Septal Defect to Cardiovascular Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by E7 Countries: Proportion of Atrial Septal Defect to Cardiovascular Clinical Trials 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Sponsors 21
Top Companies Participating in Atrial Septal Defect Therapeutics Clinical Trials 22
Prominent Drugs 23
Clinical Trial Profile Snapshots 24
Appendix 32
Abbreviations 32
Definitions 32
Research Methodology 33
Secondary Research 33
About GlobalData 34
Contact Us 34
Disclaimer 34
Source 35

List of Tables
Atrial Septal Defect Therapeutics, Global, Clinical Trials by Region, 2016* 5
Atrial Septal Defect Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Atrial Septal Defect Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Atrial Septal Defect Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
Atrial Septal Defect Therapeutics Clinical Trials, Europe, Top Countries, 2016* 9
Atrial Septal Defect Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Proportion of Atrial Septal Defect to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 11
Atrial Septal Defect Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 12
Atrial Septal Defect Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 13
Proportion of Atrial Septal Defect to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 14
Atrial Septal Defect Therapeutics, Global, Clinical Trials by Phase, 2016* 15
Atrial Septal Defect Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 16
Atrial Septal Defect Therapeutics, Global, Clinical Trials by Trial Status, 2016* 17
Atrial Septal Defect Therapeutics Clinical Trials, Global, by End Point Status, 2016* 18
Atrial Septal Defect Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 19
Atrial Septal Defect Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 20
Atrial Septal Defect Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 21
Atrial Septal Defect Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 22
Atrial Septal Defect Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 23

List of Figures
Atrial Septal Defect Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Atrial Septal Defect Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Atrial Septal Defect Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Atrial Septal Defect Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 8
Atrial Septal Defect Therapeutics Clinical Trials, Europe, Top Countries (%), 2016* 9
Proportion of Atrial Septal Defect to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 11
Atrial Septal Defect Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 12
Atrial Septal Defect Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 13
Proportion of Atrial Septal Defect to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 14
Atrial Septal Defect Therapeutics, Global, Clinical Trials by Phase (%), 2016* 15
Atrial Septal Defect Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 16
Atrial Septal Defect Therapeutics, Global, Clinical Trials by Trial Status, 2016* 17
Atrial Septal Defect Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 19
Atrial Septal Defect Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 20
Atrial Septal Defect Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 21
Atrial Septal Defect Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 22
Atrial Septal Defect Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 23
GlobalData Methodology 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Sweden

  • February 2017
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Contraceptive Market in the Netherlands

  • February 2017
    8 pages
  • Contraceptive  

  • Netherlands  

View report >

Insulin Market and Diabetes Statistics in the US

  • February 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

4 days ago

Related Market Segments :

Therapy
Cardiology
Hypertension

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.